JNK promotes the progression of castration-resistant prostate cancer

被引:2
|
作者
Feng, Yigeng [1 ]
Cao, Hongwen [1 ]
Wang, Dan [1 ]
Chen, Lei [1 ]
Gao, Renjie [1 ]
Sun, Peng [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Surg Dept 1, Urol Dept, LONGHUA Hosp, Shanghai 200032, Peoples R China
基金
中国国家自然科学基金;
关键词
Prostate cancer; PC3; prostate-specific antigen; castration; JNK; ANDROGEN DEPRIVATION THERAPY; MECHANISMS; PATHWAYS; STATISTICS; ILEXGENIN;
D O I
10.18388/abp.2020_6610
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Prostate cancer is one of the most common cancers in men worldwide. This study aims to elucidate the roles of c-Jun N-terminal kinase (JNK) in the progression of castration-resistant prostate cancer (CRPC). Methods: JNK overexpressing and knockdown cell lines were established on the PC-3 prostate cell line. qPCR and Western blotting were performed to determine the mRNA and protein levels of target genes in prostate tissues and cell lines. MTT and Matrigel invasion assays were conducted to evaluate the cell viability and invasive ability, respectively. The Kaplan-Meier estimator was performed to estimate the overall survival rate and second progression-free survival rate. Pearson's correlation coefficient was used to evaluate the relationship between JNK and prostate-specific antigen (PSA). Results: Relative JNK expression was correlated with Gleason score and PSA value in patients with CRPC. Kaplan-Meier analysis revealed that patients with low JNK expression exhibited high overall survival and second progressionfree survival rate. In vitro assays demonstrated that JNK overexpression promoted cell viability and invasion as well as the protein expressions of extracellular signalregulated kinase (ERK) and matrix metalloproteinase 1 (MMP1) in PC-3 cell lines. Conclusions: JNK overexpression promotes the development of CRPC via the regulation of ERK and MMP1.
引用
收藏
页码:817 / 822
页数:6
相关论文
共 50 条
  • [31] Strategies in castration-resistant prostate cancer
    Bessede, Th
    PROGRES EN UROLOGIE, 2011, 21 : S68 - S71
  • [32] Abiraterone and castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2013, 14 (02): : E48 - E48
  • [33] Diethylstilbestrol in castration-resistant prostate cancer
    Wilkins, Anna
    Shahidi, Mehdi
    Parker, Chris
    Gunapala, Ranga
    Thomas, Karen
    Huddart, Robert
    Horwich, Alan
    Dearnaley, David
    BJU INTERNATIONAL, 2012, 110 (11B) : E727 - E735
  • [34] The biology of castration-resistant prostate cancer
    Lian, Fei
    Sharma, Nitya V.
    Moran, Josue D.
    Moreno, Carlos S.
    CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 17 - 28
  • [35] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [36] Steroidogenesis in castration-resistant prostate cancer
    Shiota, Masaki
    Endo, Satoshi
    Blas, Leandro
    Fujimoto, Naohiro
    Eto, Masatoshi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 240 - 251
  • [37] Cabazitaxel for castration-resistant prostate cancer
    Shigeta, Keisuke
    Miura, Yuji
    Naito, Yoichi
    Takano, Toshimi
    LANCET, 2011, 377 (9760): : 121 - 121
  • [38] Enzalutamide in castration-resistant prostate cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (08): : E312 - E312
  • [39] Denosumab in castration-resistant prostate cancer
    Kyrgidis, Athanassios
    Tzellos, Thrasivoulos-George
    LANCET, 2012, 379 (9828): : E50 - E50
  • [40] Corticotherapy in castration-resistant prostate cancer
    Lebdai, S.
    Branchereau, J.
    Robert, G.
    De La Tallie, A.
    Bouchaert, P.
    PROGRES EN UROLOGIE, 2013, 23 : S23 - S33